Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (5)
Language
- English (5)
Keywords
- cancer treatment (3)
- lymph nodes (2)
- oncolytic viruses (2)
- Biochemie (1)
- adenovirus (1)
- angiogenesis (1)
- antibodies (1)
- ascites (1)
- blood (1)
- breast cancer (1)
- breast-tumors (1)
- cancer (1)
- carcinoma (1)
- carcinomas (1)
- cell cultures (1)
- enzyme-linked immunoassays (1)
- kidneys (1)
- lung and intrathoracic tumors (1)
- matrix metalloproteinases (1)
- metastasis (1)
- metastatic tumors (1)
- mice (1)
- microenvironment (1)
- mouse models (1)
- prostate (1)
- prostate cancer (1)
- renal cancer (1)
- secondary lung tumors (1)
- therapy (1)
- vaccinia virus (1)
- viral replication (1)
Virotherapy on the basis of oncolytic vaccinia virus (VACV) infection is a promising approach for cancer therapy. In this study we describe the establishment of a new preclinical model of feline mammary carcinoma (FMC) using a recently established cancer cell line, DT09/06. In addition, we evaluated a recombinant vaccinia virus strain, GLV-5b451, expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as an oncolytic agent against FMC. Cell culture data demonstrate that GLV-5b451 virus efficiently infected, replicated in and destroyed DT09/06 cancer cells. In the selected xenografts of FMC, a single systemic administration of GLV-5b451 led to significant inhibition of tumor growth in comparison to untreated tumor-bearing mice. Furthermore, tumor-specific virus infection led to overproduction of functional scAb GLAF-2, which caused drastic reduction of intratumoral VEGF levels and inhibition of angiogenesis.
In summary, here we have shown, for the first time, that the vaccinia virus strains and especially GLV-5b451 have great potential for effective treatment of FMC in animal model.